A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Capecitabine|DRUG: Olaparib
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo